Guillain-Barre Sendromu ile Prezente olan Mide Karsinomu: Olgu sunumu

Mide kanseri dünyada ve ülkemizde sık görülen kanser türlerinden biridir. Hastalar kilo kaybı, karın ağrısı, erken doygunluk hissi gibi semptomlarla başvurabilir yada erken evrede asemptomatik seyredebilir. Mide kanserine nadir olarak paraneoplastik sendromlar eşlik edebilmektedir ve Guillan-Barre paraneoplastik sendromlardan biridir. Hastamız kilo kaybı, epigastrik ağrı ve akut olarak ortaya çıkan bilateral güçsüzlük ile iç hastalıkları kliniğinde izlenmiş ve yapılan tetkiklerinde demiyelinizan sensorimotor radikülonevrit ve mide kanseri saptanmıştır. Biz olgumuzda bu birlikteliği mide kanserine bağlı paraneoplastik Guillan-Barre sendromu olarak değerlendirdik.

Anahtar Kelimeler:

Guillain-Barre sendromu, mide kanseri, paraneoplastik sendromu

Gastric cancer is one of the most common cancer types in the world and in our country. Patients may present with symptoms such as weight loss, abdominal pain, feeling of early satiety, and may be asymptomatic in early stage. Gastric cancer rarely accompanies paraneoplastic syndromes and Guillan-Barre is one of the neoplastic syndrome. Our patient was followed with weight loss, epigastric pain and acute onset bilateral weakness in the internal medicine clinic and demiyelinating sensomotor radiculoneuritis and gastric cancer were detected in the tests performed. In our present case, we considered this association as paraneoplastic Guillain-Barre syndrome due to gastric cancer.

Keywords:

Guillain-Barre syndrome, gastric cancer, paraneoplastic syndrome,

PDF

___

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137–2150.
2. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. AnnSurg 1993; 218: 583.
3. Cascinu S, Berardi R. Le Sindromi Paraneoplastiche. In: Lopez M. Oncologia Medica Pratica. Roma SEU 2005: 1723-1748
4. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130.
5. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
6. Hiev FL, Rajabally YA: Malignancy in Guillain-Barre syndrome: A twelve-year single centre study. J Neurological Sciences 2017; 375: 275-278.
7. Anderson D, Beecher G: Neurological Nuance: Hodgkin lymphoma presenting with Guillain-Barre syndrome. Muscle Nerve 2017; 55(4):601-604.
8. Schneiderbauer R. PD-1 Antibody-induced Guillain-Barre Syndrome in a patient with Metastatic Melanoma. Acta Derm Venereol 2017; 97(3): 395-396.
9. Antoine JC, Camdessanché JP: Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6: 75–86.
10. Toothaker TB, Rubin M: Paraneoplastic neurological syndromes: a review. Neurologist 2009; 15: 21–2.